Clough Capital Partners L P Takes $850,000 Position in Kymera Therapeutics, Inc. $KYMR

Clough Capital Partners L P acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,925 shares of the company’s stock, valued at approximately $850,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its stake in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics during the fourth quarter worth $63,000. Osaic Holdings Inc. lifted its holdings in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Kymera Therapeutics during the second quarter worth $73,000.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bruce Booth sold 5,900 shares of Kymera Therapeutics stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the transaction, the director owned 5,641 shares of the company’s stock, valued at $507,464.36. This trade represents a 51.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jeremy G. Chadwick sold 91,250 shares of Kymera Therapeutics stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $77.41, for a total transaction of $7,063,662.50. Following the transaction, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at $4,737,646.82. This represents a 59.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 234,357 shares of company stock valued at $19,072,496 over the last three months. 15.98% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Morgan Stanley reiterated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Citigroup lifted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. UBS Group lifted their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $117.14.

Kymera Therapeutics Stock Up 2.8%

Shares of NASDAQ KYMR opened at $89.90 on Thursday. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $103.00. The firm has a fifty day simple moving average of $82.99 and a 200 day simple moving average of $80.75. The company has a market capitalization of $7.40 billion, a PE ratio of -25.18 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter last year, the firm earned ($0.82) earnings per share. Kymera Therapeutics’s quarterly revenue was up 55.5% on a year-over-year basis. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.